CFO.selectmtd {CFO} | R Documentation |
Select the maximum tolerated dose (MTD) for the real single-drug trial
Description
Select the maximum tolerated dose (MTD) when the real single-drug trial is completed
Usage
CFO.selectmtd(target, npts, ntox,
prior.para = list(alp.prior = target, bet.prior = 1 - target),
cutoff.eli = 0.95, early.stop = 0.95, verbose = TRUE)
Arguments
target |
the target DLT rate. |
npts |
a vector containing the number of patients treated at each dose level. |
ntox |
a vector containing the number of patients who experienced DLT at each dose level. |
prior.para |
the prior parameters for a beta distribution, where set as |
cutoff.eli |
the cutoff to eliminate overly toxic doses for safety. We recommend
the default value of |
early.stop |
the threshold value for early stopping. The default value |
verbose |
set |
Details
CFO.selectmtd()
selects the MTD based on isotonic estimates of toxicity
probabilities. CFO.selectmtd()
selects as the MTD dose j^*
, for which the
isotonic estimate of the DLT rate is closest to the target. If there
are ties, we select from the ties the highest dose level when the estimate
of the DLT rate is smaller than the target, or the lowest dose level
when the estimate of the DLT rate is greater than the target. The
isotonic estimates are obtained by the pooled-adjacent-violators algorithm
(PAVA).
Value
CFO.selectmtd()
returns
target: the target DLT rate.
MTD: the selected MTD.
MTD = 99
indicates that all tested doses are overly toxic.p_est: the isotonic estimate of the DLT probablity at each dose and associated
95\%
credible interval.p_est = NA
if all tested doses are overly toxic.p_overdose: the probability of overdosing defined as
Pr(toxicity > \code{target}|data)
.p_overdose = NA
if all tested doses are overly toxic.
Note
The MTD selection and dose escalation/de-escalation rule are two independent components of the trial design. Isotonic regression is employed to select the MTD after the completion of the trial. When appropriate, another dose selection procedure (e.g., based on a fitted logistic model) can be used to select the MTD after the completion of the trial using the CFO-type design.
Author(s)
Jialu Fang, Wenliang Wang, and Guosheng Yin
References
Jin H, Yin G (2022). CFO: Calibration-free odds design for phase I/II clinical trials.
Statistical Methods in Medical Research, 31(6), 1051-1066.
Bril G, Dykstra R, Pillers C, Robertson T (1984). Algorithm AS 206: Isotonic regression in two independent variables.
Journal of the Royal Statistical Society. Series C (Applied Statistics), 33(3), 352–357.
Fang J, Yin G (2024). Fractional accumulative calibration‐free odds (f‐aCFO) design for delayed toxicity
in phase I clinical trials. Statistics in Medicine.
Examples
### select the MTD for the CFO-type single-drug trial
n <- c(3,3,27,3,0,0,0)
y <- c(0,0,4,2,0,0,0)
selmtd <- CFO.selectmtd(target=0.2, npts=n, ntox=y)
summary(selmtd)
plot(selmtd)